Analysts predict that Sierra Oncology Inc (NASDAQ:SRRA) will report earnings of ($0.19) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Sierra Oncology’s earnings. The highest EPS estimate is ($0.17) and the lowest is ($0.21). Sierra Oncology reported earnings per share of ($0.20) in the same quarter last year, which would suggest a positive year-over-year growth rate of 5%. The company is expected to issue its next earnings report on Tuesday, February 26th.
On average, analysts expect that Sierra Oncology will report full-year earnings of ($0.71) per share for the current financial year, with EPS estimates ranging from ($0.75) to ($0.68). For the next financial year, analysts anticipate that the firm will report earnings of ($0.71) per share, with EPS estimates ranging from ($0.73) to ($0.66). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Sierra Oncology.
Sierra Oncology (NASDAQ:SRRA) last released its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03).
Several equities analysts have commented on SRRA shares. Zacks Investment Research downgraded Sierra Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, August 15th. ValuEngine upgraded Sierra Oncology from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st.
NASDAQ:SRRA opened at $1.66 on Friday. The stock has a market capitalization of $126.39 million, a P/E ratio of -1.98 and a beta of 1.73. Sierra Oncology has a twelve month low of $1.48 and a twelve month high of $4.09.
A number of institutional investors have recently bought and sold shares of SRRA. JPMorgan Chase & Co. raised its position in Sierra Oncology by 91,592.6% in the first quarter. JPMorgan Chase & Co. now owns 221,896 shares of the biotechnology company’s stock valued at $459,000 after purchasing an additional 221,654 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Sierra Oncology by 171.6% in the first quarter. Dimensional Fund Advisors LP now owns 752,191 shares of the biotechnology company’s stock valued at $1,557,000 after purchasing an additional 475,288 shares during the last quarter. UBS Group AG bought a new position in Sierra Oncology in the first quarter valued at about $111,000. Millennium Management LLC raised its position in Sierra Oncology by 86.6% in the first quarter. Millennium Management LLC now owns 2,280,430 shares of the biotechnology company’s stock valued at $4,720,000 after purchasing an additional 1,058,574 shares during the last quarter. Finally, Fred Alger Management Inc. bought a new position in Sierra Oncology in the second quarter valued at about $246,000. Hedge funds and other institutional investors own 64.21% of the company’s stock.
About Sierra Oncology
Sierra Oncology, Inc, a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer.
See Also: Float
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.